Pembrolizumab plus lenvatinib and belzutifan for specified solid tumors

What is the Purpose of this Study?

What is the Condition Being Studied?

Who Can Participate in this Study?

Age Group

Adults

Participating Institutions

What is Involved?

Study Details

Full Title

[MK-6482-016] An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors

Principal Investigator

Niharika Mettu

Assistant Professor of Medicine

Protocol Number

IRB:

PRO00108150

NCT:

NCT04976634

ClinicalTrials.gov

View on ClinicalTrials.gov